Skip to main content
SpringerLink
Log in

Pharmacological and clinical profile of anastrozole

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Anastrozole (Arimidex®, 2,-2[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3- phenylene]bis(2-methyl)propiononitrile) is a novel, potent aromatase inhibitor belonging to the triazole class. In vitro and in vivo animal studies have revealed the drug to be a potent inhibitor of the aromatase enzyme with no inhibitory activity versus other enzymes involved in steroid synthesis. The drug is a potent suppressor of plasma estrogens in healthy male and postmenopausal female volunteers as well as postmenopausal breast cancer patients, and anastrozole administered as 1 mg or 10 mg daily has been shown to inhibit in vivo aromatization by 96.7 and 98.1%, respectively. Two large, randomized studies revealed anastrozole to cause objective response rates and stable disease comparable to what was achieved with megestrol acetate but with a lower incidence of side effects. While follow-up results have not revealed any significant difference in time to relapse between the drug regimens, they have revealed an improved survival among patients treated with anastrozole 1 mg compared to megestrol acetate 160 mg daily. Further follow-up is required to finally decide whether there may be a survival benefit also among patients treated with anastrozole 10 mg daily and to evaluate whether the improvement in survival is associated with an improved disease-free survival as would be anticipated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lønning PE, Kvinnsland S: Mechanism of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35: 685–710, 1988

    Article  PubMed  Google Scholar 

  2. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powels TJ, Dowsett M: The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 66: 692–697, 1992

    PubMed  CAS  Google Scholar 

  3. Dowsett M, MacNeill F, Mehta A, Newton C, Haynes B, Jones A, Jarman M, Lønning P, Powles TH, Coombes RC: Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (‘pyridoglutethimide’) in postmenopausal breast cancer patients. Br J Cancer 64: 887–894, 1991

    PubMed  CAS  Google Scholar 

  4. Steele RE, Mellor LB, Sawyer WK, Wasvary JM, Browne LJ: In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids 50: 147–161, 1987

    Article  PubMed  CAS  Google Scholar 

  5. Dowsett M, Stein RC, Mehta A, Coombes RC: Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 32: 623–634, 1990

    CAS  Google Scholar 

  6. Lønning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M: The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 63: 789–793, 1991

    PubMed  Google Scholar 

  7. Dukes M, Edwards PN, Large M, Smith IK, Boyle T: The preclinical pharmacology of ‘arimidex’ (anastrozole; ZD1033)—a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 58: 439–445, 1996

    Article  PubMed  CAS  Google Scholar 

  8. Dukes M, Edvards PN, Large M, Frank R, Yates RA, Deberardinis M, Plourde PV: ICI1033, a new, selective, non-steroidal aromatase inhibitor. Proc Am Assoc Cancer Res 33 (Abstr. 1677): 280, 1992

    Google Scholar 

  9. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Br Cancer Res Treat 30: 103–111, 1994

    Article  CAS  Google Scholar 

  10. Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ: Arimidex (ZD 1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73: 543–548, 1996

    PubMed  CAS  Google Scholar 

  11. Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A: Arimidex: A new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53: 175–179, 1995

    Article  PubMed  CAS  Google Scholar 

  12. Plourde PV, Yates RA, Dyroff M, Dukes M, Dowsett M, Demers LM, Webster A: The effect of arimidex, a new potent aromatase inhibitor, on circulating estrogens in postmenopausal women. Proc Am Assoc Clin Oncol 12 (Abstr 165): 91, 1993

    Google Scholar 

  13. Lønning PE, Helle SI, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K: Relations between sex hormones, sex hormone binding globulin, insulin-like growth facort-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin Endocrinol 42: 23–30, 1995

    Google Scholar 

  14. Jacobs S, Lønning PE, Haynes B, Griggs L, Dowsett M: Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhibition 4: 315–325, 1991

    CAS  Google Scholar 

  15. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P, Smith IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin Cancer Res 1: 1511–1515, 1995

    PubMed  CAS  Google Scholar 

  16. Geisler J, King N, Dowsett M, Ottestad L, LUndgren S, Walton P, Kormeset PO, Lønning PE: Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286–1291, 1996

    PubMed  CAS  Google Scholar 

  17. Lønning PE, Ekse D: A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatasc inhibitors. J Steroid Biochem Mol Biol 55: 409–412, 1995

    Article  PubMed  Google Scholar 

  18. Geisler J, Johannessen DC, Anker G, Lønning PE: Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: Clinical and endocrine effects. Eur J Cancer 32A: 789–792, 1996

    Article  PubMed  CAS  Google Scholar 

  19. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M: A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A: 404–412, 1996

    Article  PubMed  CAS  Google Scholar 

  20. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A: A phase III trial comparing anastrozole (1 and 10 mil ligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79: 730–739, 1997

    Article  PubMed  CAS  Google Scholar 

  21. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 14: 2000–2011, 1996

    PubMed  CAS  Google Scholar 

  22. Jonat W, Buzdar A, Howell A, Webster A, Strutt K: Significantly improved survival with arimidex (anastrozole) compared with megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC). Updated results of two randomized trials. Eur J Cancer 33 (Abstr 644): S.145, 197

  23. Lundgren S, Helle SI, Lønning PE: Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 2: 1515–1521, 1996

    PubMed  CAS  Google Scholar 

  24. Reed MJ, Topping L, Coldham NG, Purohit A, Ghilchik MW, James VHT: Control of aromatase activity in breast cancer cells: The role of cytokines and growth facotrs. J Steroid Biochem Mol Biol 44: 589–596, 1993

    Article  PubMed  CAS  Google Scholar 

  25. Reed MJ, Aherne GW, Ghilchik MW, Patel S, Chakraborty J: Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. Int J Cancer 49: 562–565, 1991

    PubMed  CAS  Google Scholar 

  26. de Jong PC, van de Ven J, Nortier HWR, Maitimu-Smeele I, Donker TH, Thijssen JHH, Slee PHTJ, Blankenstein RA: Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 57: 2109–2111, 1997

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Haukeland University Hospital, Bergen, Norway

    Per E. Lønning & Jürgen Geisler

  2. Academic Department of Biochemistry, Royal Marsden Hospital, Fulham, London, UK

    Mitch Dowsett

Authors
  1. Per E. Lønning
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jürgen Geisler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitch Dowsett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lønning, P.E., Geisler, J. & Dowsett, M. Pharmacological and clinical profile of anastrozole. Breast Cancer Res Treat 49 (Suppl 1), S53–S57 (1998). https://doi.org/10.1023/A:1006000806630

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006000806630

Search

Navigation